Delivery Order SPE2DB24D3015-SPE2DB25FGANJ
- Not listed
- The Defense Logistics Agency awarded a $3,082.67 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Benlysta 200 mg/ml auto-injector units. This competitive award, utilizing firm fixed pricing with no set-aside designation, is scheduled for completion by August 14, 2025, with fulfillment performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Benlysta is a biologic medication used primarily in the treatment of systemic lupus...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $6,165.34 for Benlysta 200 mg/ml auto-injectors on July 21, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. Benlysta (belimumab) is a biologic medication used to treat systemic lupus erythematosus and other...
- The Defense Logistics Agency awarded a delivery order valued at $6,165.34 to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on July 31, 2025, with an ultimate completion date of August 21, 2025. This firm fixed-price delivery order represents a non-set-aside, competitively awarded contract utilizing AmerisourceBergen's established indefinite delivery contract vehicle with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive global pharmaceutical support...
- The Defense Logistics Agency (DLA) awarded a Delivery Order contract to AmerisourceBergen Drug Corp for the supply of Benlysta 200 mg/ml auto-injector, with a ceiling value of $3,082.67. The contract was awarded on July 30, 2025, with an ultimate completion date of August 20, 2025, and utilizes firm fixed-price pricing under a non-competitive, non-set-aside arrangement. Performance will be executed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a...
- The Defense Logistics Agency awarded a $3,082.67 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Benlysta 200 mg/ml auto-injector units. This is a firm fixed price contract with an ultimate completion date of August 14, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract vehicle with DLA Troop Support Medical. The contract carries no set-aside designation, indicating it was competitively awarded....
- The Defense Logistics Agency awarded a delivery order valued at $3,082.67 to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on August 11, 2025, with an ultimate completion date of September 2, 2025. This competitively awarded, firm fixed-price contract with no set-aside designation will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody biologic therapy indicated for treating systemic...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp for Benlysta 200 mg/mL auto-injector, with a ceiling value of $6,165.34. The award, issued on July 28, 2025, is a firm fixed price delivery order with an ultimate completion date of August 18, 2025. This contract was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under...
- The Defense Logistics Agency awarded a $6,165.34 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injectors, with an ultimate completion date of September 5, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. Benlysta (belimumab) is a monoclonal antibody used to treat...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Benlysta 200 mg/mL auto-injectors, with a ceiling value of $3,082.67 and a completion date of August 29, 2025. This firm fixed-price delivery order is not set-aside and was competitively awarded through the vendor's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle valued through December...
- The Defense Logistics Agency awarded a $6,165.34 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector units. The contract, issued on July 22, 2025, with an ultimate completion date of August 12, 2025, represents a non-set-aside competitive award. Performance will be executed from the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen Drug Corp's larger Indefinite...
- SPE2DB24D3015Indefinite Delivery Contract
- SPE2DB24D3015-SPE2DB25FGANJDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Benlysta 200 mg/ml auto-injectors, with a ceiling value of $3,082.67 and a firm fixed price structure. This is a non-set-aside, competitively awarded contract with an ultimate completion date of September 4, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and healthcare solutions provider that serves as a critical vendor for federal medical procurement needs across military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Benlysta (belimumab) is a biologic medication used primarily for the treatment of systemic lupus erythematosus, and its inclusion in federal medical supply contracts reflects the government's commitment to providing specialized therapeutic medications to eligible beneficiaries within the Defense Health Agency and related federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.1k | 8/13/25 |